Search

Asvasiran

Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

SNX-5422

As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.

RG-7795

Fiboflapon

CPG 10101

CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials.

Lysergic acid diethylamide

Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. … However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

Stannsoporfin

Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

Tefidsogene civaparvovec

It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes … Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.

Atabecestat

Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9,

QXL138AM

QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.